Neuropathic POTS: When Nerve Damage Causes Dysautonomia

Neuropathic POTS — also called partial dysautonomic POTS or peripheral neuropathic POTS — is caused by damage to or dysfunction of the small autonomic nerve fibers that innervate blood vessels in the lower extremities. When these nerves fail to constrict leg blood vessels appropriately on standing, blood pools in the legs, venous return drops, and the heart rate surges to compensate. It is one of the most common POTS subtypes and is frequently associated with small fiber neuropathy (SFN).

The Physiology of Neuropathic POTS

In a healthy person, standing triggers a reflex arc: baroreceptors in the carotid arteries and aortic arch detect the drop in blood pressure caused by gravitational blood pooling, and sympathetic nerve signals cause vasoconstriction in the leg blood vessels to push blood back toward the heart. This reflex maintains blood pressure and limits the compensatory heart rate increase.

In neuropathic POTS, the sympathetic nerve fibers that carry vasoconstriction signals to the leg blood vessels are damaged or dysfunctional. The vasoconstriction reflex is impaired, blood pools excessively in the legs, venous return drops, and the heart rate increases dramatically to maintain cardiac output. The key feature is that the problem is peripheral (in the legs) rather than central (in the brain or spinal cord).

The Small Fiber Neuropathy Connection

Small fiber neuropathy (SFN) — damage to the small, unmyelinated C-fibers and thinly myelinated Aδ-fibers — is the most common pathological finding in neuropathic POTS. These small fibers include:

• Autonomic C-fibers: Control blood vessel tone, sweat gland activity, and gut motility
• Sensory C-fibers: Carry pain and temperature signals

In neuropathic POTS, it is primarily the autonomic C-fibers in the lower extremities that are damaged, impairing vasoconstriction. Many patients also have sensory fiber damage, producing the burning, tingling, or numbness in the feet and legs that characterizes SFN.

Skin punch biopsy — the gold standard for diagnosing SFN — shows reduced intraepidermal nerve fiber density (IENFD) in 40–60% of POTS patients in some studies, with the highest rates in neuropathic subtype patients.

Causes of Autonomic Small Fiber Neuropathy

Autoimmune. Autoimmune attack on autonomic nerve fibers is increasingly recognized as a major cause of neuropathic POTS. Antibodies against ganglionic acetylcholine receptors (gAChR), adrenergic receptors, and muscarinic receptors have been found in subsets of POTS patients. This is the mechanism underlying post-infectious POTS (including post-COVID POTS) and post-vaccination POTS.

Metabolic. Diabetes and pre-diabetes are the most common causes of SFN globally, though they typically cause a length-dependent neuropathy (starting in the feet) rather than the patchy autonomic neuropathy seen in POTS.

Inflammatory. Sjogren's syndrome, lupus, and other autoimmune conditions can cause SFN through inflammatory damage to nerve fibers.

Idiopathic. In many patients, no clear cause is identified. Genetic factors, mitochondrial dysfunction, and low-grade systemic inflammation are suspected contributors.

Diagnosis

QSART (Quantitative Sudomotor Axon Reflex Test): Measures sweat output in response to acetylcholine stimulation at four sites on the leg and foot. Reduced sweat output indicates autonomic small fiber damage. QSART is abnormal in approximately 50% of neuropathic POTS patients.

Skin punch biopsy: A 3mm punch biopsy of the lower leg skin, stained for PGP9.5 (a nerve fiber marker), measures intraepidermal nerve fiber density. Reduced IENFD confirms SFN. This is the most sensitive test for autonomic small fiber damage.

Thermoregulatory sweat test (TST): A whole-body sweat test that maps areas of anhidrosis (absent sweating), which reflect autonomic nerve damage patterns.

Plasma norepinephrine: In neuropathic POTS, standing norepinephrine is typically normal or mildly elevated (200–500 pg/mL), distinguishing it from hyperadrenergic POTS (>600 pg/mL).

Treatment

Treating the underlying cause. If autoimmune neuropathy is identified (positive autoantibodies, inflammatory markers, or biopsy showing inflammatory infiltrates), immunotherapy — IVIG, plasmapheresis, rituximab, or low-dose naltrexone — can improve or reverse nerve fiber damage. This is the most important treatment distinction for neuropathic POTS.

Volume expansion. High sodium intake, fludrocortisone, and compression garments address the downstream consequence of impaired vasoconstriction (blood pooling) even when the nerve damage itself cannot be reversed.

Midodrine. An alpha-1 agonist vasoconstrictor that compensates for the impaired sympathetic vasoconstriction. Particularly effective in neuropathic POTS because it directly replaces the missing vasoconstriction signal. Typical dose: 5–10 mg three times daily (not within 4 hours of bedtime due to supine hypertension risk).

Pyridostigmine (Mestinon). An acetylcholinesterase inhibitor that enhances neuromuscular and autonomic transmission. Particularly useful in neuropathic POTS where autonomic nerve signal transmission is impaired.

Alpha-lipoic acid. An antioxidant with evidence for improving small fiber neuropathy in diabetic patients; used by some dysautonomia specialists for idiopathic SFN-associated POTS.